Klaus P Hoeflich
Overview
Explore the profile of Klaus P Hoeflich including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
60
Citations
4457
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rich A, Chan Y, Birnbaum B, Haider K, Haimson J, Hale M, et al.
ACS Med Chem Lett
. 2024 Aug;
15(8):1169-1173.
PMID: 39140048
Optimization of the ADME properties and pharmacokinetic (PK) profile of compounds is one of the critical activities in any medicinal chemistry campaign to discover a future clinical candidate. Finding ways...
2.
Schalm S, OHearn E, Wilson K, LaBranche T, Silva G, Zhang Z, et al.
Gastro Hep Adv
. 2024 Aug;
2(3):307-321.
PMID: 39132655
Background And Aims: Fibrolamellar carcinoma (FLC) is a rare, difficult-to-treat liver cancer primarily affecting pediatric and adolescent patients, and for which precision medicine approaches have historically not been possible. The...
3.
Ryan M, Quade B, Schenk N, Fang Z, Zingg M, Cohen S, et al.
Cancer Discov
. 2024 Apr;
14(7):1190-1205.
PMID: 38588399
Alterations in the RAS-MAPK signaling cascade are common across multiple solid tumor types and are a driver for many cancers. NST-628 is a potent pan-RAF-MEK molecular glue that prevents the...
4.
Wang X, Jiang L, Thao K, Sussman C, LaBranche T, Palmer M, et al.
J Am Soc Nephrol
. 2022 Mar;
33(6):1087-1104.
PMID: 35236775
Background: Upregulation of cAMP-dependent and cAMP-independent PKA signaling is thought to promote cystogenesis in polycystic kidney disease (PKD). PKA-I regulatory subunit RI is increased in kidneys of orthologous mouse models....
5.
Kim R, Sarker D, Meyer T, Yau T, Macarulla T, Park J, et al.
Cancer Discov
. 2019 Oct;
9(12):1696-1707.
PMID: 31575541
Outcomes for patients with advanced hepatocellular carcinoma (HCC) remain poor despite recent progress in drug development. Emerging data implicate FGF19 as a potential HCC driver, suggesting its receptor, FGFR4, as...
6.
Hatlen M, Schmidt-Kittler O, Sherwin C, Rozsahegyi E, Rubin N, Sheets M, et al.
Cancer Discov
. 2019 Oct;
9(12):1686-1695.
PMID: 31575540
Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality worldwide with no clinically confirmed oncogenic driver. Although preclinical studies implicate the FGF19 receptor FGFR4 in hepatocarcinogenesis, the dependence of...
7.
Dogan T, Gnad F, Chan J, Phu L, Young A, Chen M, et al.
J Biol Chem
. 2017 Jun;
292(35):14311-14324.
PMID: 28655764
The interconnected PI3K and MAPK signaling pathways are commonly perturbed in cancer. Dual inhibition of these pathways by the small-molecule PI3K inhibitor pictilisib (GDC-0941) and the MEK inhibitor cobimetinib (GDC-0973)...
8.
Yoo C, Kang J, Kim D, Kim K, Ryoo B, Hong S, et al.
Oncotarget
. 2017 Apr;
8(24):38592-38601.
PMID: 28445152
Background: The fibroblast growth factor receptor 4 (FGFR4) pathway is an essential regulatory component of bile acid synthesis, and its relationship with hepatocellular carcinoma (HCC) has been reported. We investigated...
9.
Hoeflich K, Guan J, Edgar K, OBrien C, Savage H, Wilson T, et al.
Genes Cancer
. 2016 Jul;
7(3-4):73-85.
PMID: 27382432
Letrozole is a commonly used treatment option for metastatic hormone receptor-positive (HR+) breast cancer, but many patients ultimately relapse. Due to the importance of phosphoinositide-3 kinase (PI3K) in breast cancer,...
10.
Lee W, Crawford J, Aliagas I, Murray L, Tay S, Wang W, et al.
Bioorg Med Chem Lett
. 2016 Jun;
26(15):3518-24.
PMID: 27346791
A series of 4-azaindole-containing p21-activated kinase-1 (PAK1) inhibitors was prepared with the goal of improving physicochemical properties relative to an indole starting point. Indole 1 represented an attractive, non-basic scaffold...